Sab biotherapeutics appoints mark j. ratain, md, to the company's board of scientific advisors

Sioux falls, s.d., april 05, 2022 (globe newswire) -- sab biotherapeutics (nasdaq: sabs), (sab), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors, today announced the appointment of mark j. ratain, md, to the company's board of scientific advisors, to help advance sab's oncology platform.
SABS Ratings Summary
SABS Quant Ranking